We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Even the volumes traded looked below average 25k against an average 85k, so I'm guessing just normal statistical variation (which it certainly is, well within 2 std dev)
I had a quick look around and I can see nothing obvious, this sort of move is pretty normal for this share though
Any idea what happend for such a sharp drop?
'the Board currently expects adjusted EBITDA for the full year to be materially ahead of market expectations'
Looking forward to the July full update.
10 June 2021: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, announces the following update from Dr Miroslav Reljanovic, Executive Chairman, in advance of the Company's closed Annual General Meeting ('AGM') to be held this morning at 9.30am:
"Ergomed has had a strong start to 2021. In the year to date, the conclusion of our strategic transition to a services-based business model, coupled with our ongoing resilience globally through the COVID-19 pandemic, has enabled the Company to build further on the momentum seen in 2020.
"The Company has continued to make significant strategic progress in the current year. With the integration of the Ashfield Pharmacovigilance business successfully concluded, PrimeVigilance, the Company's pharmacovigilance division, has seen continued strong growth in revenues in line with prior trends. In the CRO business, integration of MedSource, which was acquired in December 2020, is progressing well and our CRO business as a whole is seeing further acceleration in the growth that resumed in the second half of 2020.
"Alongside strong organic growth, the integration of the two new businesses is continuing to fuel rapid development of the Company's operational presence in the US. At the same time, the Company's international growth is continuing, with ongoing expansion into further geographic areas, including the recently announced new operation in Japan, the fourth largest pharmaceutical market in the world.
"With continuing strong sales and order book growth, solid trading in the first months of the year, effective cost management and acquisition synergies, the Board currently expects adjusted EBITDA for the full year to be materially ahead of market expectations. Reported revenues for the full year are expected to be in line with market expectations, notwithstanding a higher proportion of US dollar denominated revenues leading to some FX headwinds.
"In accordance with our usual practice, in July 2021 we will provide a more detailed report on current trading and a further update on the outlook for the 2021 financial year as a whole.
"Finally, on behalf of the Board, I would like to thank all of the Company's colleagues and shareholders for their continuing support through the challenging times of the past year, as we look forward with optimism to the rest of the year."
welcome!!
Does a monthly 3 minute slam to present on companies and the only one I liked is ERGO, so I'm in. Lots of opportunity and still cash in the pocket.
ERGO has been a cracking stock to hold and seemingly completely under the radar which is an added bonus!
Looking very strong. I added some of this years ISA allowance in here and feeling rather happy.
CRO/pharmacovigilance field really hotting up with some huge deals
Https://www.reuters.com/article/ppd-ma-thermo-fisher/update-1-thermo-fisher-in-late-talks-to-buy-ppd-for-over-15-bln-wsj-idUSL4N2M746D
Some decent buying in this afternoon by somebody. Let’s hope things keep moving forward.
A cracking set of results from Ergomed:-
- Revenue up by 26.5% to £86.4m
- Gross profit up 34.6% to £39.7 m
- Cash and cash equivalents up 32.9% to £19.0 million at Dec 20
- Adjusted EBITDA up 55.2% to £19.4 million
- Order book up a stonking 55.5% at £193m
https://www.londonstockexchange.com/news-article/ERGO/audited-full-year-results/14909510
After the cracking January update the preliminary results for the year ending 31 December 2020 are out on Tuesday. ERGO have been a great investment for me so far and am very interested in how much higher they can fly.
Richard Barfield is presenting at a Shares/AJ Bell investor event on 24th March
https://www.sharesmagazine.co.uk/events/event/shares-investor-evening--webinar-240321
research-tree. com /media/ergomed-edison-open-house-interview-03-02-2021
Link below to Edison interview with Dr Miroslav Reljanovic. He seems very happy with 2020 performance - and so he should be.
https://*********************/media/ergomed-edison-open-house-interview-03-02-2021
I think the whole market is in correction see of red everywhere.
Im assuming people that the SP has come down slightly due to a falling of alot of shares but also perhaps this row about AstraZenica and the EU etc
Another cracking update from Ergomed.
- Pharmacovigilance revenue up 56% and particularly pleasing to see this includes organic growth of 30%, so increase isn't just down to acquisitive growth.
- Total revenue growth of 26.5% to £86.4 m
- Order book up by a massive 53% to £190m
- Debt free and cash increased to just under £19m despite funding 2 acquisitions during the year
https://www.investegate.co.uk/ergomed-plc--ergo-/rns/ergomed-2020-trading-update/202101260700038391M/
Revenues for 2020 are expected to be approximately £86.4 million (including £1.1 million revenues in MedSource in December 2020), an increase of 26.5% over prior year (2019: £68.3 million).
Excellent.
A number of even my good quality shares have been flat or have losses. I think the markets are down in general in the last week or so
Ahh Ok.... I hope market react any good news positively, in last few weeks i have not been have a good luck in BOO, JLP in spite of excellent results prices have moved negative direction. Since this share is already trading almost 20% below its previous peak I hope it should only move north.
Mahmas = financial year end is 31st Dec and annual report is due around March but we are also likely to get a trading update by the end of the month.
Pompal - thanks
Any day now, as per last RNS. Last years TU was 29th Jan...